Categories for Press Releases
AEON Biopharma Announces the Appointment of Alex Wilson as General Counsel
Newport Beach, Calif., August 11, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic…
AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications
Newport Beach, Calif., June 8, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA)…
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
-Topline data expected in early-2022- Newport Beach, Calif., April 5, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary…
AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine
-Clinical trial will enroll both episodic and chronic migraine patients- -Protocol utilizes streamlined treatment paradigm with fewer injections- -Topline data expected in mid-2022- Newport Beach, Calif., March 8, 2021 –…
A Transformation of the Healthcare Experience
Empowering patients, enabling specialists, and driving innovation in the health and wellness industry.
AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment
-Critical milestone transitions AEON Biopharma to clinical-stage company--Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021--Investment expected to provide funding for clinical programs…